Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae based, high-value nutrition and health products, announced financial results for the second quarter and first six months of fiscal year 2019, ended September 30, 2018.
Second Quarter Fiscal 2019
For the second quarter of fiscal 2019 compared to the second quarter of fiscal 2018, net sales were $6,954,000 compared to $8,055,000. Gross profit was $2,285,000, with gross profit margin of 32.9%, compared to gross profit of $3,620,000 and gross profit margin of 44.9%. Operating loss was ($1,004,000) compared to operating income of $619,000. Net loss was ($1,136,000) or ($0.20) per diluted share, compared to net income of $475,000 or $0.08 per diluted share.
Commenting on the second quarter and first six months results (changes shown vs. same period of fiscal 2018), Cyanotechs Chief Executive Officer, Mawae Morton, said:
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
The re-inoculation we initiated in the first quarter of this fiscal year continued to restrict supply in the second quarter, which in turn significantly reduced our net sales and gross profit margin. In addition to a 13.7% decrease in sales volume, the lower production levels resulted in a $0.6 million increase in costs for the current quarter, and reduced gross margin by 9.3 points.
We have returned to mostly normal production levels for spirulina, and as a result, the re-inoculation should not continue to have significant negative impacts on our financial results in future quarters. Demand for spirulina remains high, and at September 30 we had a large number of open spirulina orders for both Nutrex Hawaii products and Cyanotech bulk material.
Astaxanthin sales for the quarter were 0.2% higher than last year, and at the end of the quarter we had orders of $0.8 million that were still in transit to customers, compared to $0.1 million in transit at September 30, 2017. These orders will be recognized as revenue upon delivery in October 2018 and fall into our third quarter results,
Sales to Costco were up 2% and sales to Amazon were up 35% in the second quarter compared to the second quarter of fiscal 2018, reflecting continued growth with these key customers. We continued to invest in these relationships, for example, by joining Amazon as a premium sponsor during the Kona World Championship Ironman Race.
Net sales decreased 16.4% for the first six months of fiscal 2019 compared to the same period last year, driven by lower spirulina sales (down 36.8%) due to the re-inoculation of our spirulina ponds and the related fall in production. Astaxanthin sales were down 3.4% compared to the first six months of last year due to a higher volume of shipments in transit at the end of the current quarter that will be recognized as revenue in October.
The lower spirulina production levels reduced gross margin by 9.9 points for the first six months of the current year. An additional 2.8 percentage point decrease in gross profit margin resulted from a higher astaxanthin cost per kilo compared to the same period last year, due to lower production as a result of the reduced light levels that occurred during the recent Kilauea eruption.
First Six Months Fiscal 2019
For the first six months ended September 30, 2018 compared to the first six months ended September 30, 2017, net sales were $14,099,000 compared to $16,864,000. Gross profit was $4,121,000, with gross profit margin of 29.2%, compared to $7,223,000 and 42.8%. Net loss was ($2,411,000) or ($0.42) per diluted share, compared to net income of $977,000 or $0.17 per diluted share.
Trailing 12 Months
For the trailing 12 months ended September 30, 2018 compared to the trailing 12 months ended September 30, 2017, net sales were $31,350,000 compared to $31,722,000. Gross profit was $10,269,000, with gross profit margin of 32.8%, compared to $12,741,000 and 40.2%. Net loss was ($2,363,000) or ($0.41) per diluted share, compared to net income of $354,000 or $0.06 per diluted share.
Please review the Companys Form 10-Q for the period ended September 30, 2018 for more detailed information.
Cyanotech will host a Skype broadcast at 8 p.m. EDT on Tuesday, November 13 to respond to questions about its operating results and other topics of interest. Interested parties are asked to submit questions to [email protected] before 12 p.m. EDT on Tuesday November 13. The Company will respond only to relevant questions relating to the Companys second quarter fiscal 2019 financial performance, and will not be accepting any questions or comments during the broadcast. To join the broadcast, please browse http://cyanotech.com/meet approximately five minutes prior to the start time.
About Cyanotech Cyanotech Corporation, a world leader in microalgae technology for over 30 years, produces BioAstin Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica. These all natural, dietary ingredients and supplements leverage our experience and reputation for quality, building nutritional brands which promote health and well-being. The Companys mission is to fulfill the promise of whole health through Hawaiian microalgae. Cyanotechs BioAstin offers superior antioxidant activity which supports skin, eye and joint health, as well as recovery from exercise*. Cyanotechs Spirulina products offer nutrition that supports cardiovascular health and immunity.* All Cyanotech products are produced from microalgae grown at our 90-acre facility in Kona, Hawaii using patented and proprietary technology and are Generally Recognized as Safe (GRAS) for use in food products. Cyanotech sells its products direct to consumers at retail locations in the United States and online at www.nutrex-hawaii.com and also distributes to dietary supplement, nutraceutical and cosmeceutical manufacturers and marketers. The Company is regulated by the FDA. Visit www.cyanotech.com for more information.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995 Besides statements of present fact and historical fact, this press release may contain forward-looking statements. Forward-looking statements relate to the future and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by forward-looking statements. We caution against relying on forward-looking statements. Important factors that could change actual, future results include: changes in sales levels to our largest customers, weather patterns in Hawaii, production problems, risks associated with new products, foreign exchange fluctuations, and availability of financing, as well as national and global political, economic, business, competitive, market and regulatory conditions. Other factors are more fully detailed in the Companys annual Form 10-K filings with the Securities and Exchange Commission.
Financial Tables Follow: The following tables do not contain footnotes or other information contained in the Companys Form 10-Q for the period ended September 30, 2018, which can be found on the Cyanotech website (www.cyanotech.com) under Investors>Investor Filings upon filing. As such the following Financial Tables are provided only as a guide and other factors are more fully detailed in the Companys annual Form 10-K filings with the Securities and Exchange Commission.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)
September 30, 2018
March 31, 2018
|Accounts receivable, net of allowance for doubtful accounts of $27 at September 30, 2018 and $27 at March 31, 2018||1,882||2,664|
|Prepaid expenses and other current assets||700||590|
|Total current assets||13,684||13,617|
|Equipment and leasehold improvements, net||15,122||15,734|
|LIABILITIES AND STOCKHOLDERS EQUITY|
|Line of credit||1,750||500|
|Current maturities of long-term debt||663||655|
|Total current liabilities||7,602||5,707|
|Long-term debt, less current maturities||5,482||5,790|
|Other long-term liabilities||93||103|
|Commitments and contingencies|
|Preferred stock of $0.01 par value, authorized 10,000,000 shares; no shares issued and outstanding|
|Common stock of $0.02 par value, shares authorized 50,000,000; 5,836,110 shares issued and outstanding at September 30, 2018 and 5,772,032 shares at March 31, 2018||117||115|
|Additional paid-in capital||32,280||32,051|
|Total stockholders equity||15,927||18,107|
|Total liabilities and stockholders equity||$||29,104||$||29,707|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
Three Months Ended September 30,
Six Months Ended September 30,
|COST OF SALES||4,669||4,435||9,978||9,641|
|General and administrative||1,481||1,412||2,853||2,764|
|Sales and marketing||1,597||1,440||3,020||2,929|
|Research and development||211||149||419||291|
|Total operating expenses||3,289||3,001||6,292||5,984|
|(Loss) income from operations||(1,004||)||619||(2,171||)||1,239|
|Interest expense, net||(150||)||(133||)||(280||)||(241||)|
|(Loss) income before income taxes||(1,154||)||486||(2,451||)||998|
|INCOME TAX (BENEFIT) EXPENSE||(18||)||11||(40||)||21|
|NET (LOSS) INCOME||$||(1,136||)||$||475||$||(2,411||)||$||977|
|NET (LOSS) INCOME PER SHARE:|
|SHARES USED IN CALCULATION OF NET (LOSS) INCOME PER SHARE:|
Bruce Russell, (310) 346-6131